| アブストラクト | INTRODUCTION: Miller Fisher syndrome (MFS) is typically associated with a benign course and spontaneous recovery. However, immunotherapies such as intravenous immunoglobulin (IVIG) and plasma exchange (PE) are often administered for this condition because of the potential for clinical deterioration. We aimed to evaluate the real-world use of immunotherapies in MFS management using a nationwide Japanese database. METHODS: We conducted a retrospective cohort study between April 2014 and March 2020 using the Japanese Diagnosis Procedure Combination database. Patient demographics and treatment modalities were described. Outcomes included length of hospital stay, in-hospital mortality, hospitalization cost, and activities of daily living defined by the Barthel index score. RESULTS: We identified 1,595 patients with MFS. Of these, 999 (62.6%) received immunotherapy (including IVIG for 908 [56.9%] patients, intravenous methylprednisolone for 219 [13.7%] patients, and PE for 18 [1.8%] patients). In patients with and without immunotherapy, the median length of hospital stay was 18 and 12 days, in-hospital mortality was 0.7% and 0.2%, median total hospitalization costs were yen1,660,200 and yen549,375, and the proportions of Barthel index score of 95-100 at discharge were 75.3% and 75.2%, respectively. CONCLUSION: Our findings highlight the widespread use of immunotherapies for MFS in Japan despite its generally favorable natural course. |
|---|
| ジャーナル名 | Annals of clinical epidemiology |
|---|
| Pubmed追加日 | 2026/3/9 |
|---|
| 投稿者 | Kodama, Satoshi; Kainaga, Mitsuhiro; Aso, Shotaro; Jo, Taisuke; Hashimoto, Yohei; Matsui, Hiroki; Yasunaga, Hideo; Shirota, Yuichiro; Hamada, Masashi; Fushimi, Kiyohide; Toda, Tatsushi |
|---|
| 組織名 | Department of Neurology, Graduate School of Medicine, The University of Tokyo,;Tokyo, Japan.;Department of Neurology, University of Iowa Hospital and Clinics, Iowa City,;Iowa, USA.;Department of Health Services Research, Graduate School of Medicine, The;University of Tokyo, Tokyo, Japan.;Department of Clinical Epidemiology and Health Economics, School of Public;Health, The University of Tokyo, Japan.;Save Sight Institute, The Faculty of Medicine and Health, The University of;Sydney, Sydney, Australia.;Department of Clinical Laboratory Medicine, Graduate School of Medicine, The;Department of Health Policy and Informatics, Institute of Science Tokyo Graduate;School, Tokyo, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41798215/ |
|---|
